Clinical Research Directory

Inclusion Criteria: 1. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen; 2. Moderate ARDS characterized by the following criteria: * Invasive mechanical ventilation with a minimum PEEP of 5 cm H2O; * PaO2/FiO2 ≤200 that may be estimated from pulse oximetry or determined by arterial blood gas; * No evidence of volume overload or heart failure; 3. The patient is ≥18 years of age at the time of consent; 4. QTcF interval ≤ 440 milliseconds; 5. A female patient of childbearing potential must not attempt to become pregnant for 39 months, and if sexually active with a male partner, is willing to practice acceptable methods of birth control for 39 months after the last dose of study drug; 6. A male patient who is sexually active with a female partner of childbearing potential is willing to practice acceptable methods of birth control for 39 months after the last dose of study drug. A male patient must not donate sperm for 39 months; 7. The patient is willing and able to, or has a legal authorized representative (LAR) who is willing and able to, provide informed consent to participate, and to cooperate with all aspects of the protocol. Exclusion Criteria: 1. Expected survival or time to withdrawal of life-sustaining treatments expected to be \<7 days. 2. ECMO; 3. Suspected septic shock; 4. The patient has a history of: * Organ or hematologic transplant; * HIV; * Active hepatitis B or hepatitis C infection; 5. Current treatment with: * Chemotherapy; * Immunosuppressive medications or immunotherapy (see Section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; * Hemodialysis or Peritoneal Dialysis; 6. The patient is known to be pregnant or is nursing; 7. Currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; 8. Allergy to eggs or any of the excipients in study drug.